Wilbanks Smith & Thomas Asset Management’s Allergan plc AGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-3,163
Closed -$463K 445
2019
Q1
$463K Buy
+3,163
New +$459K 0.03% 245
2018
Q4
Sell
-89
Closed -$17K 1498
2018
Q3
$17K Buy
+89
New +$16.4K ﹤0.01% 929
2017
Q4
Sell
-1,017
Closed -$208K 366
2017
Q3
$208K Sell
1,017
-50
-5% -$11.6K 0.02% 319
2017
Q2
$259K Sell
1,067
-588
-36% -$138K 0.02% 264
2017
Q1
$395K Sell
1,655
-191
-10% -$44.5K 0.03% 200
2016
Q4
$388K Buy
1,846
+495
+37% +$103K 0.03% 190
2016
Q3
$311K Buy
1,351
+9
+0.7% +$2.2K 0.03% 211
2016
Q2
$310K Buy
1,342
+130
+11% +$30K 0.03% 216
2016
Q1
$325K Sell
1,212
-34
-3% -$9.73K 0.04% 210
2015
Q4
$389K Sell
1,246
-34
-3% -$10.1K 0.04% 180
2015
Q3
$348K Buy
1,280
+320
+33% +$98.3K 0.05% 185
2015
Q2
$291K Buy
960
+22
+2% +$6.56K 0.03% 238
2015
Q1
$279K Sell
938
-2
-0.2% -$570 0.03% 239
2014
Q4
$242K Buy
+940
New +$235K 0.02% 266

Other funds holding AGN

Wilbanks Smith & Thomas Asset Management's AGN Position: Q2 2019 in Review

Wilbanks Smith & Thomas Asset Management sold out of Allergan plc (AGN) in Q2 2019, closing a stake of 3,163 shares — an estimated $463K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in AGN in Q4 2014 and held it in 14 quarters. The position peaked at $463K in Q1 2019. 971 funds tracked by Wall St. Rank hold AGN as of Q2 2019.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Allergan plc position as of Q2 2019 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 3,163 Allergan plc shares in Q2 2019, an estimated $463K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Allergan plc in Q4 2014 and held it in 14 quarters.
  • Wilbanks Smith & Thomas Asset Management's Allergan plc position peaked at $463K in Q1 2019.
  • 971 funds tracked by Wall St. Rank held Allergan plc as of Q2 2019.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q2 2019, filed 7 Aug 2019.